Navigation Links
NeurogesX, Inc. Announces $20 Million Private Placement

SAN MATEO, Calif., July 22, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, today announced that on July 21, 2011 it entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors and, subject to standard closing conditions, is expected to receive approximately $20 million in gross proceeds from the sale of 11,749,552 shares of its common stock and the issuance of five-year warrants to purchase 5,874,782 additional shares of NGSX common stock at an exercise price of $1.65 per share. The purchase price per unit of shares and warrants (with one unit being comprised of one share of common stock and a warrant to purchase 0.5 shares of common stock) is $1.72, and is based on the $1.65 per share consolidated closing bid price of NGSX common stock on the NASDAQ Global Market on July 21, 2011.

Leerink Swann LLC served as the exclusive placement agent for the transaction.  Roth Capital Partners and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE AMEX: LTS) acted as financial advisors to the Company for the transaction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements. NeurogesX has agreed to file a registration statement with the Commission covering the resale of the shares of common stock, including shares of common stock issuable upon exercise of the warrants, sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and patient enrollment has been completed in a Phase 2 clinical trial of NGX-1998 in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza; the potential benefits of Qutenza and NGX-1998; expected proceeds and closing of the private placement; and the registration of any shares issued directly or indirectly in connection with the private placement.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; potential alternative therapies; and difficulties or delays in the private placement closing or the registration of the private placement shares with the Securities and Exchange Commission. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310

The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

Victoria Aguiar (media)

(646) 536-7013

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
(Date:10/8/2015)... MANASSAS, Va. , Oct. 8, 2015  ATCC, ... announces today that it has been selected by The ... provide vital cell lines to academic, pharmaceutical, and biotechnology ... the United States , ... --> the United States , ...
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a ... expansion into the North American market with the establishment ... and Europe , has ... of Target Enrichment methodology and sample preparation for DNA ... facilitates both hereditary and somatic genetic testing more accurately, ...
(Date:10/8/2015)... October 8, 2015 Global ... Global Biologics and Biosimilars industry . --> ... Biologics and Biosimilars Industry 2015 Deep Market Research ... is a professional and depth research report on ... ) , --> ...
(Date:10/8/2015)... , Oct. 8, 2015  Today, DuPont and ... for genome editing, jointly announced a strategic alliance. ... cross-licensed their respective patent portfolios, with DuPont receiving ... in major row crops, and non-exclusive rights in ... --> --> In ...
Breaking Biology Technology:
... Annual Samter Journalism Awards ... Entry Deadline: October 31, 2007, MILWAUKEE, ... (AAAAI), the largest professional medical specialty,organization in the United States ... a special interest in the research and treatment of allergic ...
... CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech ... oral,presentation covering interim results from a U.K. ... for patients with advanced or,metastatic cancers is ... Cancer,Research Institute (NCRI) conference on October 2, ...
... Sept. 28 Cynosure, Inc.,(Nasdaq: CYNO ), ... array of,light-based aesthetic treatment systems, today announced that ... Company/MEDACorp Aesthetics Roundtable,Conference. Chief Financial Officer Timothy ... recent financial results in a presentation,beginning at 2:10 ...
Cached Biology Technology:
(Date:10/8/2015)... , 8. Oktober 2015 Die ... tätiges Unternehmen des Bereiches Tracking, hat heute ... der Gefängnisbehörde Virginias (Department of Corrections – ... Überwachungsdienste für alle Strafen geliefert werden, die ... , Präsident für den Amerikanischen Kontinent der ...
(Date:10/7/2015)... October 8, 2015 --> ... Fingerprint Cards (FPC) during third quarter 2015 amounted to around ... around 860 MSEK that was communicated 20 August 2015. ... strengthened delivery capacity and a continued growing demand for the ... estimated to be higher than during the third quarter. The ...
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
Breaking Biology News(10 mins):
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... Zaragoza (UNIZAR) has studied precipitation trends in Spain,s 10 ... results show that precipitation has declined overall between the ... the rainy season. The rains are heavier in October ... 1946, the average precipitation falling on Spanish hydrological basins ...
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
Cached Biology News:
... Epitope: aa 16-25 of human GSK3 ... Recommended Storage: Store vial at -20 C prior ... extended storage aliquot contents and freeze at -20 C or ... Family: Other Sub-Family: not ...
S-100 alpha/beta chain (8B10)...
... Acetate: CoA ligase (AMP forming), Acetate thiokinase ... protein content. Physical form: Lyophilized ... and reduced glutathione Preparation Unit ... of S-acetyl coenzyme A from acetate, ATP ...
SCCRO (S-17)...
Biology Products: